[go: up one dir, main page]

MX2014014924A - Compuestos de azetidina y piperidina utiles como inhibidores de pde10. - Google Patents

Compuestos de azetidina y piperidina utiles como inhibidores de pde10.

Info

Publication number
MX2014014924A
MX2014014924A MX2014014924A MX2014014924A MX2014014924A MX 2014014924 A MX2014014924 A MX 2014014924A MX 2014014924 A MX2014014924 A MX 2014014924A MX 2014014924 A MX2014014924 A MX 2014014924A MX 2014014924 A MX2014014924 A MX 2014014924A
Authority
MX
Mexico
Prior art keywords
azetidine
piperidine compounds
compounds useful
pde10 inhibitors
pde10
Prior art date
Application number
MX2014014924A
Other languages
English (en)
Inventor
Jian J Chen
Qingyian Liu
Thomas T Nguyen
Wenge Zhong
Jennifer R Allen
Alexander J Pickrell
Wenyuan Qian
Robert M Rzasa
Michael J Frohn
Matthew Richard Kaller
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48692687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014014924(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2014014924A publication Critical patent/MX2014014924A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos de azetidina y piperidina de fórmula (I) (ver Fórmula) (I), como se define en la memoria descriptiva, las composiciones que los contienen y procesos para preparar dichos compuestos e intermediarios de los mismos. También se dan a conocer en el presente métodos para tratar trastornos cognitivos o enfermedades que pueden tratarse mediante la inhibición de PDE10, tal como enfermedad de Huntington, esquizofrenia, trastorno bipolar, trastorno obsesivo-compulsivo y similares.
MX2014014924A 2012-06-14 2013-06-14 Compuestos de azetidina y piperidina utiles como inhibidores de pde10. MX2014014924A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261659911P 2012-06-14 2012-06-14
PCT/US2013/045768 WO2013188724A1 (en) 2012-06-14 2013-06-14 Azetidine and piperidine compounds useful as pde10 inhibitors

Publications (1)

Publication Number Publication Date
MX2014014924A true MX2014014924A (es) 2015-03-09

Family

ID=48692687

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014924A MX2014014924A (es) 2012-06-14 2013-06-14 Compuestos de azetidina y piperidina utiles como inhibidores de pde10.

Country Status (25)

Country Link
US (3) US8691986B2 (es)
EP (1) EP2864317A1 (es)
JP (1) JP2015519402A (es)
KR (1) KR20150023417A (es)
CN (1) CN104619694A (es)
AP (1) AP2014008136A0 (es)
AR (1) AR091436A1 (es)
AU (1) AU2013274153B2 (es)
BR (1) BR112014031368A2 (es)
CA (1) CA2875802A1 (es)
CL (1) CL2014003391A1 (es)
CO (1) CO7160011A2 (es)
CR (1) CR20150012A (es)
EA (1) EA201590014A1 (es)
HK (1) HK1203935A1 (es)
IL (1) IL235901A0 (es)
MA (1) MA37748B1 (es)
MX (1) MX2014014924A (es)
PE (1) PE20150348A1 (es)
PH (1) PH12014502780A1 (es)
SG (1) SG11201408168UA (es)
TN (1) TN2014000510A1 (es)
TW (1) TWI508959B (es)
UY (1) UY34858A (es)
WO (1) WO2013188724A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34300B1 (fr) 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
UY34858A (es) * 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
MX2012013128A (es) * 2010-05-13 2013-03-20 Amgen Inc Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10.
WO2011143495A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
AU2011253058A1 (en) * 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
MA34300B1 (fr) 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
UY34858A (es) * 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10

Also Published As

Publication number Publication date
TW201412729A (zh) 2014-04-01
CN104619694A (zh) 2015-05-13
BR112014031368A2 (pt) 2017-06-27
JP2015519402A (ja) 2015-07-09
HK1203935A1 (en) 2015-11-06
CL2014003391A1 (es) 2015-07-10
MA37748A1 (fr) 2016-11-30
PE20150348A1 (es) 2015-03-04
TWI508959B (zh) 2015-11-21
WO2013188724A1 (en) 2013-12-19
SG11201408168UA (en) 2015-01-29
EP2864317A1 (en) 2015-04-29
CA2875802A1 (en) 2013-12-19
AP2014008136A0 (en) 2014-12-31
US9303028B2 (en) 2016-04-05
US20130338138A1 (en) 2013-12-19
US20160176874A1 (en) 2016-06-23
CO7160011A2 (es) 2015-01-15
IL235901A0 (en) 2015-09-24
MA37748B1 (fr) 2017-07-31
AR091436A1 (es) 2015-02-04
US20140148435A1 (en) 2014-05-29
UY34858A (es) 2013-11-29
TN2014000510A1 (en) 2016-03-30
KR20150023417A (ko) 2015-03-05
US9493459B2 (en) 2016-11-15
AU2013274153A1 (en) 2014-12-18
PH12014502780A1 (en) 2015-02-02
US8691986B2 (en) 2014-04-08
AU2013274153B2 (en) 2016-05-19
EA201590014A1 (ru) 2015-04-30
CR20150012A (es) 2015-02-11

Similar Documents

Publication Publication Date Title
PH12012502212A1 (en) Nitrogen heterocyclic compounds usefulas pde10 inhibitors
CA2871471C (en) Dna-pk inhibitors
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
IN2014CN04907A (es)
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
WO2014152965A3 (en) Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EA201100749A1 (ru) Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
NZ708928A (en) Mannose derivatives for treating bacterial infections
MY186456A (en) Quinazoline carboxamide azetidines
MX357502B (es) Derivados de pirrolotriazinona.
MX2012004548A (es) Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
PH12014502780A1 (en) Azetidine and piperidine compounds useful as pde10 inhibitors
HK1176618A (en) Nitrogen heterocyclic compounds useful as pde10 inhibitors
MX2014002343A (es) Inhibidores de parp.
TN2010000488A1 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents